News
ICPE 2023 Featured Presentations from Analysis Group Consultants
Analysis Group presented a symposium, podium presentation, and six research posters at the 39th annual International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) in Halifax, Nova Scotia.
Chief Epidemiologist and Managing Principal Mei Sheng Duh and Vice President Marianne Cunnington presented a symposium titled “Bias Introduced by COVID-19 Related Healthcare Disruptions in Safety and Effectiveness Studies: Proposing Methodological Solutions,” during which they described a new method that they developed to adjust for bias introduced by COVID-19-associated health care disruptions in RWE studies. Dr. Duh and Dr. Cunnington were joined by speakers from GSK, the London School of Hygiene & Tropical Medicine, and the European Medicines Agency.
Additionally, Dr. Duh participated in the podium presentation of “Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Comparing Female Patients with Recurrent Versus Non-recurrent Uncomplicated Urinary Tract Infection in the United States.” This study was coauthored by Analysis Group consultants and researchers from GSK and Hackensack University Medical Center.
Further details on the symposium, podium presentation, and posters are available in our ICPE 2023 Presentation Guide.
During the conference, Dr. Cunnington, who was elected to ISPE’s Board, took office as the representative for industry and service providers in Europe and Africa. Analysis Group is proud to have supported this conference as a gold sponsor.
Associated People
Marianne Cunnington
Managing PrincipalDr. Cunnington specializes in regulatory epidemiology, including the design and execution of real-world post-marketing safety and effectiveness studies, as well as real-world studies to support the approval of new products through innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for new product submissions with regulators across multiple geographies (US, UK, Europe, Japan, South Korea); post-approval safety studies in the EU; post-marketing requirement and commitment studies in the US; and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington spent more than 20 years as a pharmaceutical industry epidemiologist focusing on the generation of real-world evidence (RWE) to support the development and life cycle management of vaccines and pharmacological therapies. Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical RWE projects, provided epidemiological expertise for the company’s Global Safety Board, and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington serves on the board of the International Society for Pharmacoepidemiology as an elected representative of European industry and service providers.